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Abstract
Introduction: The apolipoprotein E (APOE) ε4 allele associates with memory impair-
ment in neurodegenerative diseases. Its association with memory after mild traumatic 
brain injury (mTBI) is unclear.
Methods: mTBI patients (Glasgow Coma Scale score 13–15, no neurosurgical inter-
vention,	 extracranial	Abbreviated	 Injury	 Scale	 score	≤1)	 aged	≥18	years	with	APOE 
genotyping	 results	 were	 extracted	 from	 the	 Transforming	 Research	 and	 Clinical	
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1  | INTRODUCTION
Mild traumatic brain injury (mTBI) is a major cause of cognitive impair-
ment, which may be modulated in part by genetic susceptibility. mTBIs 
constitute 70%–90% of all traumatic brain injuries (TBI) (Cassidy et al., 
2004);	 it	 is	 estimated	 that	 20%–25%	 of	 patients	 experience	 per-
sistent symptoms and/or cognitive and neuropsychiatric deficits at 
6–12	months	postinjury	(Arciniegas,	Anderson,	Topkoff,	&	McAllister,	
2005).	A	major	health	system	challenge	 is	 that	 individuals	with	sim-
ilar injuries will often manifest different symptoms, follow divergent 
clinical trajectories, and have varied functional outcomes (Ponsford, 
Draper,	&	Schönberger,	2008).
Apolipoprotein	 E	 (APOE)	 encodes	 a	 lipoprotein	 (ApoE)	 released	
primarily by astrocytes after TBI and is known to promote neuronal 
survival/outgrowth	and	exert	antioxidant	effects	in	the	context	of	ox-
idative	stress	and	neuroinflammation	 (Figure	1).	ApoE	 is	a	key	 regu-
lator of plasma lipid levels produced in abundance in the brain along 
with	ApoE	receptors	in	order	to	mediate	synaptic	repair,	remodeling,	
and	protection	(Blackman,	Worley,	&	Strittmatter,	2005;	Ignatius	et	al.,	
1986;	Nathan	et	al.,	1994).	The	gene	for	ApoE	is	located	on	chromo-
some 19 and is highly polymorphic (Friedman et al., 1999). Differences 
in the tertiary structure and in the charge distribution of the APOE 
isoforms determine the capacity for cholesterol homeostasis through 
binding to receptors, to other proteins, and through intracellular 
trafficking	pathways	and	second	messengers	(Strittmatter	&	Bova	Hill,	
2002;  Saito et al., 2003). These differences in metabolic regulation 
may influence the outcome after brain injury. Of its three common al-
leles (ε2, ε3, ε4), ε4—which	has	reduced	antioxidant	and	biological	ac-
tivity—is a risk factor for neurodegenerative disorders. While APOE-ε2 
and ε3,	respectively,	contain	two	and	one	cysteine	residues	for	detox-
ifying	cytotoxic	products	of	lipid	peroxidation,	APOE-ε4	expresses	two	
arginine residues and lacks this ability. Hence, APOE-ε4 is directly as-
sociated	with	mitochondrial	toxicity	and	beta-	amyloid	deposition	con-
tributing	to	Alzheimer’s	Disease	(AD)	in	a	dose-	dependent	manner	(ε4 
carrier,	5-	fold;	ε4/ε4:	20-	fold)	(Blennow,	Mattsson,	Schöll,	Hansson,	&	
Zetterberg,	2015;	Hauser	&	Ryan,	2013).
The APOE-ε4 allele has been associated with unfavorable out-
comes following TBI, including acute clinical deterioration, increased 
hemorrhage, longer hospital stays, and impaired functional recovery 
(Chiang,	Chang,	&	Hu,	2003;	Jiang	et	al.,	2007;	Alexander	et	al.,	2007).	
This	could	be	due	to	increased	expression	of	APOE in astrocytes fol-
lowing ischemic brain injury and neuronal degeneration (Friedman 
et al., 1999), furthered by the association between APOE-ε4 and in-
creased	 oxidative	 stress	 (Jiang	 et	al.,	 2006).	 In	 a	 landmark	 study	 of	
984	patients	by	Teasdale	et	al.	in	2005,	the	APOE-ε4 allele was associ-
ated with decreased functional recovery after controlling for Glasgow 
Coma Scale (GCS) motor score, pupillary reactivity, and intracranial 
computed tomography (CT) pathology; ε4 carriers under age 45 years 
3U01NS086090-	03S1,	5U01NS086090-	02,	
5U01NS086090-	03;	US	DOD	W81XWH-	
13-	1-	0441,	US	DOD	W81XWH-	14-	2-	0176	
(to G. T. M.)
Knowledge	 in	 Traumatic	 Brain	 Injury	 Pilot	 (TRACK-	TBI	 Pilot)	 study.	 Cohorts	 deter-
mined by APOE-ε4(+/−)	were	assessed	for	associations	with	6-	month	verbal	memory,	
measured	 by	 California	 Verbal	 Learning	 Test,	 Second	 Edition	 (CVLT-	II)	 subscales:	
Immediate	Recall	Trials	1–5	(IRT),	Short-	Delay	Free	Recall	(SDFR),	Short-	Delay	Cued	
Recall	 (SDCR),	 Long-	Delay	Free	Recall	 (LDFR),	 and	Long-	Delay	Cued	Recall	 (LDCR).	
Multivariable	 regression	 controlled	 for	 demographic	 factors,	 seizure	 history,	 loss	 of	
consciousness, posttraumatic amnesia, and acute intracranial pathology on computed 
tomography (CT).
Results: In 114 mTBI patients (APOE-ε4(−)=79; APOE-ε4(+)=35), ApoE-ε4(+) was asso-
ciated	with	long-	delay	verbal	memory	deficits	(LDFR:	B = −1.17	points,	95%	CI	[−2.33,	
−0.01],	p = .049; LDCR: B = −1.58	[−2.63,	−0.52],	p = .004), and a marginal decrease on 
SDCR (B = −1.02	[−2.05,	0.00],	p = .050). CT pathology was the strongest predictor of 
decreased verbal memory (IRT: B = −8.49,	SDFR:	B = −2.50,	SDCR:	B = −1.85,	LDFR:	
B = −2.61,	LDCR:	B = −2.60;	p < .001).	Seizure	history	was	associated	with	decreased	
short-	term	memory	(SDFR:	B = −1.32,	p = .037; SDCR: B = −1.44,	p = .038).
Conclusion: The APOE-ε4	allele	may	confer	an	increased	risk	of	impairment	of	6-	month	
verbal memory for patients suffering mTBI, with implications for heightened surveil-
lance	and	targeted	therapies.	Acute	 intracranial	pathology	remains	the	driver	of	de-
creased verbal memory performance at 6 months after mTBI.
K E Y W O R D S
apolipoprotein E, genetic factors, human studies, outcome measures, traumatic brain injury, 
verbal memory
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were conferred up to 25 additional years of aging after suffering TBI 
(Teasdale,	Murray,	&	Nicoll,	 2005).	 In	moderate	 and	 severe	TBI	 pa-
tients	assessed	at	least	6	months	postinjury,	Ariza	et	al.	(2006)	found	
that ε4-	carriers	performed	notably	worse	on	tests	of	frontal	lobe	func-
tion	and	long-	term	memory.	In	a	large	Australian	cohort	stratified	by	
age, the APOE-ε4 allele was associated with poorer baseline episodic 
memory and slower reaction time in younger adults with a history of 
childhood TBI (Eramudugolla et al., 2014). Similarly, ε4 carriers may 
be at more risk for cognitive impairment and chronic traumatic en-
cephalopathy	 (CTE)	 (Liberman,	 Stewart,	Wesnes,	&	Troncoso,	 2002;	
Müller	et	al.,	2009;		Lenihan	&	Jordan,	2015;	).	Conversely	in	children,	
Moran et al. report that the APOE-ε4 allele has little impact on neuro-
cognitive measures following TBI, although ε4-	carriers	were	 associ-
ated with a more negative early response to injury (Moran et al., 2009), 
which	mirrors	the	adult	 literature	 (Friedman	et	al.,	1999;	Jiang	et	al.,	
2006). Interestingly, pediatric ε4 carriers sustaining moderate to se-
vere	TBI	showed	poorer	adaptive	functioning	in	the	context	of	positive	
parenting,	whereas	non-	ε4-carriers displayed worse detriments in the 
context	 of	 less	 optimal	 parenting	 (Treble-	Barna	 et	al.,	 2016).	 These	
studies further highlight the pleiotropic association between APOE-ε4 
and neurobehavioral outcomes after TBI, and underscore the need 
to elucidate its relationship with outcome subdomains after different 
types of TBI.
To	 date,	mild-	to-	moderate	TBI	 studies	 in	 the	 literature	 have	 re-
ported	mixed	 associations	 for	 verbal	memory	 outcome	 by	APOE-ε4 
status	(Chamelian,	Reis,	&	Feinstein,	2004;	Han	et	al.,	2007;	Padgett,	
Summers,	Vickers,	McCormack,	&	Skilbeck,	2016).	 Interestingly,	Han	
and colleagues reported improved neuropsychological outcome at 1 
month was associated with APOE-ε4 in the military population (Han 
et al., 2007), whereas Crawford et al. (2002) reported memory and 
verbal impairment in military personnel with APOE-ε4 within 6 months 
of	 injury.	Using	 an	 extensive	neuropsychological	 battery	 at	 3	 and	6	
weeks postinjury, Liberman et al. (2002) reported in adults with mild 
and moderate TBI that patients with the APOE-ε4 allele had lower 
F IGURE  1 Effects of APOE	on	Aβ	metabolism	and	postinjury	repair.	Neuronal	injury	upregulates	astrocyte	secretion	of	ApoE,	which	clears	
lipid cell debris and assists in cholesterol delivery for synaptogenesis. APOE	is	lipidated	to	form	ApoE	lipoprotein,	and	in	the	extracellular	space	
binds	in	an	isoform-	dependent	pattern	(APOE-ε2, -ε3 >  APOE-ε4)	to	soluble	beta-	amyloid	protein	(Aβ),	a	peptidic	neurotoxin.	APOE genotype 
determines	the	capacity	for	Aβ clearance and parenchymal amyloid plaque accumulation. Evidence suggests that relative to APOE-ε2 and -ε3, 
APOE-ε4 is preferentially susceptible to proteolytic degradation, thus reducing the capacity to fulfill postinjury needs for membrane repair and 
synaptogenesis
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mean scores for nearly all neuropsychological tests and needed more 
time to complete tasks, although none of the differences were sig-
nificant. The authors suggested that APOE genotype may specifically 
influence the severity of the acute injury along with delaying recovery. 
In concussed athletes tested within 6 months of injury, carriers of the 
ε4 allele demonstrated greater neurocognitive variability than athletes 
without an ε4	allele	(Merritt,	Rabinowitz,	&	Arnett,	2017).	However,	an	
Indian	cohort	of	mild-	to-	moderate	TBI	patients	at	6	months	showed	no	
clear differences in neuropsychological test performance by APOE-ε4 
status (Pruthi et al., 2010). Reports of association between ε4 carriers 
and	postconcussional	symptoms	months	to	years	postinjury	also	exist	
(Sundström	et	al.,	 2007;	 	Merritt	&	Arnett,	2016;	 	Pan	et	al.,	 2016).	
Population characteristics and TBI severity may contribute to the dis-
crepancies in the current literature. Hence, the association of APOE-ε4 
status and subdomains of verbal memory performance following iso-
lated mTBI warrant further study.
For	the	current	analysis,	we	utilized	data	from	the	prospective	mul-
ticenter	Transforming	Research	and	Clinical	Knowledge	 in	Traumatic	
Brain	Injury	Pilot	(TRACK-	TBI	Pilot)	study	(Yue	et	al.,	2013)	to	explore	
associations between APOE	and	components	of	6-	month	verbal	mem-
ory postinjury. We demonstrate that the APOE-ε4 carrier status is spe-
cifically	associated	with	decreased	performance	on	 long-	delay	 recall	
trials,	without	effects	on	immediate	recall	or	short-	delay	recall	trials.
2  | METHODS
2.1 | Study design
The	 TRACK-	TBI	 Pilot	 study	 is	 a	 multicenter	 prospective	 obser-
vational study conducted at three Level I Trauma Centers in the 
U.S.—San Francisco General Hospital (SFGH), University of Pittsburgh 
Medical Center (UPMC), and University Medical Center Brackenridge 
(UMCB)	 in	 Austin,	 Texas—using	 the	 National	 Institutes	 of	 Health	
(NIH) National Institute of Neurological Disorders and Stroke (NINDS) 
TBI	 Common	 Data	 Elements	 (CDEs)	 (Yue	 et	al.,	 2013;	 Maas	 et	al.,	
2010; Duhaime et al., 2010; Manley et al., 2010; Wilde et al., 2010). 
Inclusion	criteria	for	TRACK-	TBI	Pilot	were	external	force	trauma	to	
the head presenting to Level I trauma center, and clinically indicated 
head	CT	scan	within	24	hr	of	injury.	Exclusion	criteria	were	pregnancy,	
comorbid	life-	threatening	disease,	incarceration,	psychiatric	hold,	and	
non-	English	speaking	due	to	limitations	in	participation	with	outcome	
assessments.
As	the	goal	of	the	current	analysis	was	to	investigate	the	associ-
ation between the APOE-ε4	allele	and	6-	month	verbal	memory	out-
come	after	mTBI,	uncomplicated	by	massive	intracranial	trauma	[e.g.,	
CT	evidence	of	mixed	density	 lesions	>25	mm,	midline	shift	>5	mm,	
or	 evidence	of	 cisternal	 compression	 (Marshall	 et	al.,	 1992)]	 or	 pol-
ytrauma,	patients	were	included	if	≥18	years	of	age,	with	GCS	score	
of 13–15 at ED admission per current definition of mTBI (Teasdale 
&	Jennett,	1974;	),	Marshall	CT	Score	1–2	(Marshall	et	al.,	1992),	no	
acute	neurosurgical	 intervention,	and	no	extracranial	 injuries	greater	
than	“mild”	(Abbreviated	Injury	Scale	[AIS]	score	>1	in	any	extracranial	
body region). To preserve the integrity of cognitive outcomes analysis, 
patients with a baseline history or diagnosis of central nervous sys-
tem	 (CNS)	 tumor,	 cerebrovascular	 accident	 (CVA),	 schizophrenia,	bi-
polar disorder, learning disability, and/or developmental delay were 
excluded	from	analysis.
Eligible patients were enrolled through convenience sampling at 
all three sites. Procedures followed were in accordance with the eth-
ical	standards	of	the	responsible	committee	on	human	experimenta-
tion	and	with	 the	Helsinki	Declaration	of	1975,	 as	 revised	 in	2008.	
Institutional Review Board (IRB) approval was obtained at all partic-
ipating sites. Informed consent was obtained for all patients prior to 
enrollment in the study. For patients unable to provide consent due to 
their	injury,	consent	was	obtained	from	their	legally	authorized	repre-
sentative	(LAR).	Patients	were	then	re-	consented,	if	cognitively	able,	at	
later	inpatient	and/or	outpatient	follow-	up	assessments	for	continued	
participation in the study.
2.2 | Biospecimen acquisition and genotyping
Specimen	 acquisition	 was	 performed	 as	 previously	 described	 (Yue	
et al., 2013). In brief, blood samples were collected via peripheral ven-
ipuncture	or	existing	peripheral	venous	or	arterial	indwelling	catheters	
within	24	hr	of	 injury	 for	DNA	genotyping.	 Samples	were	 collected	
in	BD	Vacutainer	K2-	EDTA	vacutainer	tubes,	then	aliquoted	and	fro-
zen	in	cryotubes	at	−80°C	within	1	hr	of	collection	in	accordance	with	
recommendations from the NIH NINDS CDE Biomarkers Working 
Group	 (Manley	 et	al.,	 2010).	DNA	was	 extracted	 from	 isolated	 leu-
kocytes	 using	 the	 Wizard®	 Genomic	 DNA	 Purification	 Kit	 as	 de-
scribed by the manufacturer (Promega, Madison, WI). APOE (rs7412; 
rs429358)	 polymorphisms	were	 genotyped	using	 the	TaqMan®SNP 
Genotyping	Assay	 (Applied	Biosystems,	Carlsbad,	CA;	rs7412	Assay	
ID#	C____904973_10;	rs429358	Assay	ID#	C___3084793_20).	APOE 
alleles were determined as ε2	(rs7412(T)/rs429358(T)),	ε3 (rs7412(C)/
rs429358(T),	or	ε4	(rs7412(C)/rs429358(C));	no	ε1	cases	existed	in	the	
dataset. For the purposes of evaluating a potential deleterious effect 
of the APOE-ε4 allele, patients with ε2/ε2, ε2/ε3, and ε2/ε3 genotypes 
were grouped as APOE-ε4(−), and ε3/ε4 or ε4/ε4 genotypes were 
grouped as APOE-ε4(+), similar to previous studies (Teasdale et al., 
2005;	Sundström	et	al.,	2007).
2.3 | Outcome measures
The	California	Verbal	Learning	Test,	Second	Edition	(CVLT-	II)	is	a	ver-
bal learning and memory task with five learning trials, an interference 
trial, an immediate recall trial performed with and without cues, and a 
post-	20	min	recall	trial	performed	with	and	without	cues.	The	CVLT-	II	
was	substituted	 for	 the	Rey	Auditory	Verbal	Learning	Test	 (RAVLT)	
listed in the NIH NINDS outcome CDEs due to relevant revisions of 
the	 Second	 Edition	 and	 higher	 consistency	 on	 between-	norm	 sets	
(Stallings,	Boake,	&	Sherer,	1995).	The	CVLT-	II	has	been	used	in	over	
200	published	clinical	and	experimental	research	studies	as	a	measure	
of	episodic	verbal	learning	and	memory	(Woods,	Delis,	Scott,	Kramer,	
&	Holdnack,	2006).	It	has	also	been	found	to	be	one	of	the	most	sen-
sitive tests for detecting residual brain damage in patients with brain 
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trauma, able to differentiate between outcomes following mild versus 
moderate-	severe	TBI	 (Davis,	 2016;	 	Delis,	Kramer,	Kaplan,	&	Ober,	
2000). Researchers have found that the CVLT can also accurately pre-
dict functional outcomes at the time of testing, including level of cur-
rent disability, type of current supervision, and return to work status 
(Hanks,	Jackson,	&	Crisanti,	2016).
The	CVLT-	II	subscales	allow	for	differentiation	between	encoding,	
consolidation,	and	retrieval	deficits	(Vanderploeg,	Crowell,	&	Curtiss,	
2001).	 Lower	 scores	on	 the	CVLT-	II	 Short-	Delay	Free	Recall	 (SDFR)	
indicate	 retroactive	 interference,	while	 lower	 scores	 on	 the	CVLT-	II	
Long-	Delay	Free	Recall	(LDFR)	score	indicate	the	occurrence	of	rapid	
forgetting. Free recall trials reflect the degree to which words on the 
first	list	are	recalled	without	assistance.	Cued	recall	trials	assist	the	ex-
aminee in two ways: (1) by informing them of the categorical structure 
of the list; and (2) requiring them to use semantic clustering in recalling 
the target words. Patients with mild cognitive impairment (MCI) will 
often demonstrate aberrant responses on cued recall trials. Patients 
with more severe deficits will typically respond with deficits on both 
free and cued recall trials.
2.4 | Statistical analysis
Descriptive statistics are presented as means and standard deviations 
(SD) for continuous variables and as proportions for categorical vari-
ables. Group differences in demographics and injury characteristics 
across APOE-ε4	 genotypes	were	 assessed	by	Pearson’s	 chi-	squared	
test (X2)	 for	categorical	variables,	and	analysis	of	variance	 (ANOVA)	
for	continuous	variables.	Fisher’s	Exact	Test	was	used	 to	assess	 for	
differences	 in	 categorical	 variables	 with	 individual	 cell	 counts	 ≤5.	
Multivariable linear regression was performed to assess the associa-
tion between APOE-ε4	genotype	and	each	of	the	five	CVLT-	II	outcome	
measures. Demographic and injury variables were selected based on 
recommendations and cited predictive value in large studies and sys-
tematic reviews in mTBI to include age in years (scalar), education in 
years	(scalar),	sex	(male	vs.	female),	race	(dichotomized	to	Caucasian	
vs. other due to small samples of other races), loss of consciousness 
(LOC;	no	vs.	yes/unknown),	posttraumatic	amnesia	(PTA;	no	vs.	yes/
unknown), and presence of intracranial pathology on initial head com-
puted	 tomography	 (CT)	 scan	 (Jacobs	 et	al.,	 2010;	 Kashluba,	 Hanks,	
Casey,	&	Millis,	2008;	Van	der	Naalt,	2001;	Carroll	et	al.,	2004).	A	his-
tory	of	seizures	has	been	correlated	with	decreased	verbal	memory	
performance in the neurology literature and hence prior medical his-
tory	(PMH)	of	seizures	was	included	to	serve	as	a	surrogate	for	base-
line	cognitive	burden	(Blake,	Wroe,	Breen,	&	McCarthy,	2000;	Schefft	
et	al.,	2008;	Berl	et	al.,	2005).	To	prevent	overfitting,	we	adhered	to	
the rule of 10 for multiple regression analysis (predictors=9; n = 114) 
(Howell, 2013; Green, 1991; ). To account for attributable variance 
(R2),	a	two-	tiered	approach	was	employed	for	each	multivariable	re-
gression model. First, demographic and injury history predictors were 
entered	onto	 the	model	 for	each	CVLT-	II	outcome	measure	and	R2 
was recorded (Table S1); then, APOE-ε4 status was entered onto 
the model, and the new R2 as well as the ΔR2 from the model with-
out APOE-ε4 status was calculated and reported. The multivariable 
regression mean differences (B) and their associated 95% confidence 
intervals (CI) are reported for each predictor in the regression analy-
ses. When appropriate, the regression means and standard errors (SE) 
are reported for APOE-ε4(+) and APOE-ε4(−) cohorts. Significance was 
assessed at α	=	0.05.	 All	 analyses	 were	 performed	 using	 Statistical	
Package for the Social Sciences (SPSS) version 22 (IBM Corporation, 
Chicago,	IL,	USA).
3  | RESULTS
3.1 | Demographic and injury characteristics
In total, 114 patients were included in the current analysis (Table 1). 
The majority were male (67%) and of Caucasian race (73%). Mean 
age	was	42.8	±	16.2	years,	and	education	level	was	14.2	±	2.9	years.	
Mechanisms of injury included fall (46%), motor vehicle accident 
(21%), cyclist/pedestrian struck by vehicle (14%), assault (14%), and 
struck	 by/against	 object	 (4%).	 Approximately,	 12%	 of	 patients	 re-
ported	 PMH	 of	 seizures,	 while	 23%	 reported	 absence	 of	 LOC	 and	
40%	reported	absence	of	PTA.	ED	GCS	deficit	(<15)	occurred	in	20%	
of patients, and 25% of patients showed evidence of acute intracra-
nial pathology on initial head CT. APOE genotypes were distributed as 
follows: ε2/ε3 n = 12 (11%), ε3/ε3 n = 67 (59%), ε3/ε4 n = 29 (25%), 
ε2/ε4 n = 3 (3%), and ε4/ε4 n = 3 (3%). Breakdown by ethnicities were: 
Caucasian: ε2/ε2 = 11, ε3/ε3 = 47, ε3/ε4 = 22, ε2/ε4 = 1, ε4/ε4 = 2; 
African-	American/African:	ε2/ε4 = 2, ε3/ε3 = 7, ε3/ε4 = 6, ε4/ε4 = 1; 
other races: ε2/ε3 = 1, ε3/ε3 = 13, ε3/ε4 = 1. Overall, 31% of patients 
were APOE-ε4(+). APOE distribution conformed to Hardy–Weinberg 
equilibrium (allelic frequencies: ε2 = 0.0658,	ε3 = 0.7675, ε4 = 0.1667; 
χ2 =0.554, df=5, p = .990).
Demographic and injury characteristics by APOE-ε4 carrier status 
are shown in Table 1. Notably, ApoE-ε4(+) patients were older (49.6 
vs. 39.7 years, p = .002). APOE-ε4 carrier status differed across races, 
with	 African-	American/African	 patients	 showing	 the	 highest	 inci-
dence, followed by Caucasians (p = .012); the higher prevalence of 
the ε4	allele	in	African-	American/African	patients,	and	of	the	ε3 allele 
in Caucasians, is consistent with prior epidemiological reports (Farrer 
et	al.,	1997;	Kern	et	al.,	2015).	No	other	demographic	or	injury	history	
differences were observed by APOE-ε4 carrier status.
3.2 | APOE-ε4(+) is not associated with immediate 
recall or short- delay recall at 6 months postinjury
For IRT, no significant differences were observed by APOE-ε4 status 
(p = .190).	Increasing	age	was	associated	with	decreasing	recall	(per-	
year B = −0.28,	95%	CI	[−0.40,	−0.16];	p < .001). Increasing education 
was	associated	with	 improved	recall	 (per-	year	B = 0.89	 [0.26,	1.53];	
p = .006).	Caucasian	 race	was	associated	with	a	5.42-	point	 increase	
([1.33,	9.50],	p = .010)	compared	to	other	races.	PTA+	patients	were	
associated	 with	 a	 5.15-	point	 decrease	 ([−9.01,	 −1.19],	 p = .011). 
Patients with intracranial CT pathology showed a mean decrease of 
8.49-	points	([−12.64,	−4.34],	p < .001) (Table 2). The ΔR2 from adding 
APOE-ε4	status	was	+0.010.
6 of 13  |     YUE Et al.
For SDFR, no significant differences were observed by APOE-ε4 
status (p = .129)	(Figure	2).	Age	was	associated	with	decreased	recall	
(per-	year	B = −0.08	 [−0.12,	 −0.04];	p < .001). Education was associ-
ated	with	 improved	 recall	 (per-	year	B = 0.23	 [0.03,	 0.44];	 p = .023). 
Caucasian race (B = 1.38	[0.08,	2.68],	p = .037) and intracranial CT pa-
thology (B = −2.50	[−3.81,	−1.18],	p < .001) remained predictors. The 
ΔR2 from adding APOE-ε4	status	was	+0.012.
For	Short-	Delay	Cued	Recall	(SDCR),	APOE-ε4(+) patients showed 
a marginal decrease in performance (B = −1.02	[−2.05,	0.00],	p = .050) 
compared with their APOE-ε4(−)	 counterparts	 (Figure	2).	 Age	 was	
associated	with	decreased	 recall	 (per-	year	B = −0.07	 [−0.10,	 −0.04];	
p < .001).	 Education	 was	 associated	 with	 improved	 recall	 (per-	year	
B = 0.18	 [0.02,	 0.34];	p = .029). Caucasian race remained protective 
(B = 1.15	 [0.12,	 2.19),	 p = .029), while CT pathology was deleteri-
ous (B = −1.85	 [−2.90,	 −0.85],	 p < .001).	 Having	 experienced	 PTA	
(B = −1.03	 [−2.03,	−0.03],	p = .043)	 and	PMH	of	 seizures	 (B = −1.44	
[−2.81,	−0.08],	p = .038)	emerged	as	predictors.	The	ΔR2 from adding 
APOE-ε4	status	was	+0.023.
TABLE  1 Demographic and clinical 
information of included patients with mild 
traumatic brain injury
Variable
Overall 
(N = 114)
APOE ε4(−)
 (N = 79)
APOE ε4(+)
(N = 35) Sig. (p)
Age	(years)
Mean	±	SD 42.8	±	16.2 39.7	±	16.5 49.6	±	13.6 .002
Gender
Male 76 (67%) 49 (62%) 27 (77%) .114
Female 38	(33%) 30	(38%) 8	(23%)
Race
Caucasian 83	(73%) 58	(70%) 25 (30%) .012
African-	American/African 16 (14%) 7 (44%) 9 (56%)
Other races 15 (13%) 14 (93%) 1 (7%)
PMH	Seizures
No 100	(88%) 70	(89%) 30	(86%) .664
Yes 14 (12%) 9 (11%) 5 (14%)
Education (years)
Mean	±	SD 14.2	±	2.9 14.3	±	3.1 13.7	±	2.1 .280
Mechanism of injury
Motor vehicle accident 24 (21%) 17 (22%) 7 (20%) .910
Cyclist/pedestrian hit 16 (14%) 11 (14%) 5 (14%)
Fall 53 (47%) 38	(48%) 15 (43%)
Assault 16 (14%) 10 (13%) 6 (17%)
Struck by/against object 5 (4%) 3 (4%) 2 (6%)
Loss of consciousness
No 26 (23%) 19 (24%) 7 (20%) .634
Yes/unknown 88	(77%) 60 (76%) 28	(80%)
Posttraumatic amnesia
No 46 (40%) 30	(38%) 16 (46%) .437
Yes/unknown 68	(60%) 49 (62%) 19 (54%)
ED arrival GCS
13–14 23 (20%) 16 (20%) 7 (20%) .975
15 91	(80%) 63	(80%) 28	(80%)
CT pathology
Absent 85	(75%) 58	(73%) 27 (77%) .674
Present 29 (25%) 21 (27%) 8	(23%)
Race	distributions	are	reported	as	row	percentages.	All	other	distributions	reported	as	column	percent-
ages.	The	 race	subgroup	 “Other	 races”	was	combined	due	 to	 individual	 small	 sample	sizes	of	Asian	
[N = 6; ε4(−) = 5, ε4(+) = 1],	 American	 Indian/Alaskan	 Native	 [N = 1; ε4(−) =	1],	 Hawaiian/Pacific	
Islander	[N = 2; ε4(−) =	2],	and	more	than	one	race	[N = 6; ε4(−) =	6].	ED	Arrival	GCS	was	combined	due	
to N = 1 for GCS 13 in both APOE groups.
APOE, apolipoprotein E; CI, confidence interval; ED, emergency department; GCS, Glasgow Coma 
Scale; PMH, prior medical history; SD, standard deviation.
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3.3 | APOE-ε4(+) is associated with impaired long- 
delay recall at 6 months postinjury
For LDFR, APOE-ε4(+) patients showed a significant decrease in ver-
bal memory function (B = −1.17	 [−2.33,	 −0.01],	 p = .049) compared 
with APOE-ε4(−)	(Figure	2).	Age	was	associated	with	decreased	recall	
TABLE  2 Multivariable regression of APOE-ε4 status and 
6-	month	verbal	memory	subscales
Variable B [95% CI] Sig. (p)
Immediate Recall Trials 1–5 (R2 = 0.405; ΔR2	=	+0.010)
APOE-ε4(+) −2.69	[−6.72,	1.36] .190
Age	(per-	year) −0.28	[−0.40,	−0.16] <.001
Education	(per-	year) 0.89	[0.26,	1.53] .006
Sex	(male) −0.28	[−4.15,	3.59] .886
Race (Caucasian) 5.42	[1.33,	9.50] .010
PMH	Seizures	(yes) −4.13	[−9.53,	1.26] .132
LOC (yes/unknown) 1.07	[−3.48,	5.62] .641
PTA	(yes/unknown) −5.15	[−9.10,	−1.19] .011
CT Pathology (yes) −8.49	[−12.64,	−4.34] <.001
Short-	Delay	Free	Recall	(R2 = 0.356; ΔR2	=	+0.012)
APOE-ε4(+) −0.99	[−2.27,	0.29] .129
Age	(per-	year) −0.08	[−0.12,	−0.04] <.001
Education	(per-	year) 0.23	[0.03,	0.44] .023
Sex	(male) 0.01	[−1.21,	1.24] .985
Race (Caucasian) 1.38	[0.08,	2.68] .037
PMH	Seizures	(yes) −1.32	[−3.03,	0.39] .129
LOC (yes/unknown) 0.55	[−0.89,	1.99] .451
PTA	(yes/unknown) −0.99	[−2.24,	0.29] .122
CT Pathology (yes) −2.50	[−3.81,	−1.18] <.001
Short-	Delay	Cued	Recall	(R2	=	0.380;	ΔR2	=	+0.023)
APOE-ε4(+) −1.02	[−2.05,	0.00] .050
Age	(per-	year) −0.07	[−0.10,	−0.04] <.001
Education	(per-	year) 0.18	[0.02,	0.34] .029
Sex	(male) 0.50	[−0.48,	1.48] .310
Race (Caucasian) 1.15	[0.12,	2.19] .029
PMH	Seizures	(yes) −1.44	[−2.81,	−0.08] .038
LOC (yes/unknown) 0.27	[−0.88,	1.42] .644
PTA	(yes/unknown) −1.03	[−2.03,	−0.03] .043
CT Pathology (yes) −1.85	[−2.90,	−0.85] <.001
Long-	Delay	Free	Recall	(R2 = 0.415; ΔR2	=	+0.022)
APOE-ε4(+) −1.17	[−2.33,	−0.01] .049
Age	(per-	year) −0.08	[−0.11,	−0.04] <.001
Education	(per-	year) 0.22	[0.03,	0.42] .010
Sex	(male) 0.58	[−0.53,	1.69] .304
Race (Caucasian) 1.69	[0.58,	2.87] .005
PMH	seizures	(yes) −1.49	[−3.05,	0.06] .059
LOC (yes/unknown) 0.45	[−0.86,	1.76] .499
PTA	(yes/unknown) −1.28	[−2.42,	−0.14] .028
CT pathology (yes) −2.61	[−3.80,	−1.42] <.001
Long-	Delay	Cued	Recall	(R2	=	0.408;	ΔR2	=	+0.050)
APOE-ε4(+) −1.58	[−2.63,	−0.52] .004
Age	(per-	year) −0.06	[−0.09,	−0.03] <.001
Education	(per-	year) 0.16	[−0.01,	0.32] .062
Sex	(male) 0.44	[−0.57,	1.45] .386
(Continues)
Variable B [95% CI] Sig. (p)
Race (Caucasian) 1.14	[0.07,	2.20] .038
PMH	Seizures	(yes) −0.96	[−2.38,	0.45] .180
LOC (yes/unknown) 0.35	[−0.83,	1.54] .556
PTA	(yes/unknown) −0.69	[−1.73,	0.34] .186
CT Pathology (yes) −2.60	[−3.69,	−1.52] <.001
Tier 2 of the hierarchical multivariable linear regression with the response 
variables being five verbal memory subscales of the California Verbal 
Learning	Test,	Second	Edition	(CVLT-	II).	Mean	increase	or	decrease	(B) and 
associated	 95%	 confidence	 intervals	 [95%	 CI]	 are	 reported	 for	 each	
predictor.
APOE, apolipoprotein E; CT, computed tomography; LOC, loss of 
	consciousness;	PMH,	prior	medical	history;	PTA,	posttraumatic	amnesia.
TABLE  2  (Continued)
F IGURE  2 Six-	month	verbal	memory	performance,	by	APOE-ε4 
carrier	status.	Performance	on	four	CVLT-	II	subscales	(SDFR,	Short-	
Delay	Cued	Recall	(SDCR),	Long-	Delay	Free	Recall	(LDFR),	LDCR)	at	
6 months postinjury are shown for 114 mTBI patients, by APOE-ε4 
carrier	status.	Raw	scores	for	each	CVLT-	II	subscale	are	controlled	
for	age,	education,	sex,	race,	prior	medical	history	(PMH)	seizures,	
loss of consciousness, posttraumatic amnesia, and acute intracranial 
pathology on head CT scan. Multivariable regression means and 
95% confidence intervals are shown for APOE-ε4 groups. APOE-
ε4(−), blue; APOE-ε4(+), red. APOE, apolipoprotein E; CT, computed 
tomography;	CVLT-	II,	California	Verbal	Learning	Test,	Second	Edition;	
LDCR,	Long-	Delay	Cued	Recall;	LDFR,	Long-	Delay	Free	Recall;	mTBI,	
mild	traumatic	brain	injury;	PMH,	prior	medical	history;	SDCR,	Short-	
Delay	Cued	Recall;	SDFR,	Short-	Delay	Free	Recall
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(per-	year	B = −0.08	 [−0.11,	 −0.04];	p < .001). Education was associ-
ated	with	 improved	 recall	 (per-	year	B = 0.22	 [0.03,	 0.42];	p = .010). 
Caucasian race remained protective (B = 1.69	[0.58,	1.69],	p = .005), 
while	PTA+	(B = −1.28	[−2.42,	−0.14],	p = .028)	and	CT	pathology	re-
mained deleterious (B = −2.61	[−3.80,	−1.42],	p < .001). The ΔR2 from 
adding APOE-ε4	status	was	+0.022.
For	Long-	Delay	Cued	Recall	(LDCR),	APOE-ε4(+) patients showed 
a similar decrease in recall ability (B = −1.58	[−2.63,	−0.52],	p = .004) 
compared with APOE-ε4(−)	 (Figure	2).	 Age	was	 associated	with	 de-
creased	recall	(per-	year	B = −0.06	[−0.09,	−0.03];	p < .001). Education 
was	 associated	 with	 marginally	 improved	 recall	 (per-	year	 B = 0.16 
[−0.01,	0.32];	p = .062). Caucasian race remained protective (B = 1.14 
[0.07,	2.20],	p = .038),	while	CT	pathology	(B = −2.60	[−3.69,	−1.52],	
p < .001) continued to be deleterious to verbal memory function. The 
ΔR2 from adding APOE-ε4	status	was	+0.050.
4  | DISCUSSION
In	a	prospective	study	examining	the	association	between	APOE-ε4 and 
verbal memory deficits after isolated mTBI, we find that APOE-ε4(+) 
is	 independently	associated	with	 impaired	 long-	delay	 free	and	cued	
recall at 6 months postinjury when compared with APOE-ε4(−) pa-
tients. We also demonstrate that intracranial CT pathology remains 
a	 strong	 independent	 driver	 of	 decreased	 6-	month	 verbal	 memory	
performance after mTBI.
4.1 | APOE expression, distribution, and function
ApoE	is	synthesized	primarily	by	astrocytes,	with	some	neuronal	ex-
pression	(Aoki	et	al.,	2003;	Orihara	&	Nakasono,	2002;	]	and	used	for	
cell	membrane	repair,	growth	of	neurites,	and	synaptogenesis.	ApoE	
facilitates neuronal repair processes in deep brain structures includ-
ing	the	hippocampus,	entorhinal	complex,	parahippocampal	gyrus,	and	
basal ganglia (Crawford et al., 2002), areas essential to memory con-
solidation processes which are consistently damaged following TBI 
(Bigler,	1987;		Bigler,	Anderson,	&	Blatter,	2002;	Graham,	Lawrence,	
Adams,	Doyle,	&	McLellan,1988).	 Studies	measuring	 cerebral	 blood	
flow (CBF) demonstrated that APOE-ε4(+) patients showed nega-
tive associations between verbal memory and decreased CBF in the 
medial	 frontal	 cortex,	 insula,	 and	 basal	 ganglia	 (Zlatar	 et	al.,	 2016).	
Nathoo et al. noted that APOE-ε4 carriers show a greater propensity 
for	 developing	 age-	related	 cognitive	 impairment,	 a	 decrease	 in	 the	
synapse-	neuron	 ratio,	 and	 an	 increased	 susceptibility	 to	 exogenous	
neurotoxins	 and	 hippocampal	 atrophy	 independent	 of	 head	 trauma	
(Nathoo,	Chetry,	van	Dellen,	Connolly,	&	Naidoo,	2003).
Increasing	 evidence	 suggests	 that	 ApoE-	ε4 can impede recov-
ery via several mechanisms, including less efficient lipid transport, 
more	beta-	amyloid	accumulation,	and	predisposition	to	cerebral	am-
yloid	angiopathy	 (Kay	et	al.,	2003;	Nicoll,	Roberts,	&	Graham,	1995;	
Greenberg,	Rebeck,	Vonsattel,	Gomez-	Isla,	&	Hyman,	1995),	increased	
inflammatory response, and impaired cerebral perfusion (Grocott et al., 
2001;	Kerr,	Kraus,	Marion,	&	Kamboh,	1999),	as	well	as	compromised	
blood–brain barrier and marked cerebral edema (Methia et al., 2001; 
Lynch et al., 2002). Previous work from the veteran population have 
shown that APOE-ε4(+)	 patients	 experienced	 more	 difficulty	 with	
memory compared to those who were APOE-ε4(−) following equally 
severe	TBI,	as	measured	on	 the	CVLT-	II	verbal	memory	and	 fluency	
measures	 at	 6	 months	 (Crawford	 et	al.,	 2002).	 Similarly,	 Anderson	
et al. (2009)showed poorer verbal intellectual and verbal memory 
skills in those who were APOE-ε4(+), although the differences were 
not statistically significant after adjusting for multiple comparisons. 
Of	note,	ApoE-	ε4 has been associated with verbal memory deficits in 
mTBI	but	not	with	the	other	aspects	of	executive	function.	Significant	
hippocampal atrophy and temporal horn enlargement have a tendency 
to occur after TBI, and between 2–7 months postinjury, temporal 
horn volumes correlated with measured intelligence quotients, while 
hippocampal volume correlated with verbal memory function (Bigler 
et	al.,	2002).	Findings	in	APOE-	knockout	mice	after	TBI	demonstrated	
marked learning deficits associated with neuronal death specifically 
in	the	hippocampus.	Thus,	ApoE	is	proposed	to	play	a	key	role	in	the	
neuronal repair of the hippocampus and the surrounding regions 
through	 isoform-	dependent	 clearance	 of	 beta-	amyloid	 depositions	
after	trauma	(Fagan	&	Holtzman,	2000).
4.2 | APOE-ε4(+) associates with impaired long- term 
verbal memory following mTBI
The	 CVLT-	II	 tests	 encoding,	 consolidation,	 and	 retrieval.	 The	 long-	
delay recall subtests assess forgetting rates over longer intervals and 
provide a score of retention in the absence of retroactive interference 
(Delis et al., 2000). Encoding measures the relative rate of learning. 
Consolidation is a postencoding process that involves maintenance, 
elaboration,	 and	 storage	 of	 new	 information	 in	 long-	term	 memory	
(LTM). Evidence in the moderate and severe TBI literature has yielded 
mixed	results—Vanderploeg	et	al.	 (2001)	report	no	difference	 in	en-
coding did not differ between TBI and controls on SDFR and SDCR, 
while Noe, Ferri, Colomer, Moliner, and Chirivella (2010) found APOE 
genotype to be associated with the trajectory of cognitive recovery 
but not in memory rehabilitation. In concussed athletes, APOE-ε4(+) 
patients demonstrated greater neurocognitive variability compared 
to	noncarriers	(Merritt	et	al.,	2017),	and	in	mild-	to-	moderate	TBI	pa-
tients, Lieberman reported nonsignificant decreases in performance 
across a range of neuropsychological tests for APOE-ε4(+) patients 
(Liberman et al., 2002). Similarly, in a small study of 34 patients fol-
lowing mTBI, APOE-ε4(+)	 was	 associated	 with	 decreased	 within-	
person postinjury performance on three of nine neuropsychological 
tests (Sundstrom et al., 2004). Interestingly and importantly we find 
that, in mTBI patients, subtests of encoding (IRT, SDFR, SDCR) are 
unaffected or marginally affected by APOE-ε4(+) status, while sub-
tests of consolidation are worsened by APOE-ε4(+) status. Hence, we 
extend	 the	 findings	 that	 information	 not	 properly	 consolidated	will	
rapidly	decay	from	LTM,	thus	becoming	poorly	recognized	on	LDFR	
and LDCR (Vanderploeg et al., 2001). While the R2 values for the 
regression models are relatively low, they are reasonable for human 
studies; the 2.2%–5.0% increase in R2 from the addition of APOE-ε4 
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status	for	LDFR	and	LDCR,	while	small,	is	in	line	with	expectations	in	a	
multifactorial model consisting of other validated predictors for mTBI 
outcome, and is deserving of attention considering it is from a single 
gene, but should not be overinterpreted. The value, and equipoise, of 
evaluating APOE as a locus of susceptibility and a target for interven-
tion following mTBI remains to be determined in future prospective 
studies of larger scale and rigorous study design.
Padgett and colleagues describe in a literature review that the re-
lationship between APOE and cognitive function following TBI is com-
plex	 and	 requires	 a	 nuance-	based	 approach—which	 can	 be	 partially	
elucidated through analysis of specific deficits in appropriate TBI sub-
populations	(e.g.,	mTBI	vs.	moderate/severe-	TBI;	isolated	TBI	vs.	poly-
trauma) (Padgett et al., 2016). Following mTBI, episodic verbal memory 
deficiencies are greatest between complicated mTBI and healthy con-
trols	(Tayim,	Flashman,	Wright,	Roth,	&	McAllister,	2016).	Our	analysis	
replicates this phenomenon, as CT pathology was the driver of de-
creased cognitive performance following mTBI, with greater deleteri-
ous associations with consolidation and retrieval rather than encoding. 
This supports the idea that following ischemia and neuronal damage, 
the	reduced	antioxidant	and	biological	activity	of	the	ε4	allele	may	ex-
acerbate vascular endothelial injury (Bell et al., 2012; Halliday et al., 
2016) and lead to cognitive deficits (Friedman et al., 1999). Similar 
results	 have	been	described	 in	AD	patients	with	 left	 temporal	 and/
or hippocampal damage, where a subtle decline in episodic memory 
occurs prior to the emergence of full dementia. The presence of the 
APOE-ε4	allele	increases	deposition	of	beta-	amyloid	plaques,	and	has	
been shown to independently contribute to the prediction of conver-
sion dementia when measured by tests of episodic memory such as 
the	CVLT-	II	(Lange	et	al.,	2002).
4.3 | APOE-ε4(+), demographics, and outcome
Age	and	education	effects	on	the	CVLT-	II	subscales	have	been	previ-
ously described (Delis et al., 2000). There is a known association be-
tween increasing age and decreasing performance (Delis et al., 2000; 
Wiens,	Tindall,	&	Crossen,	1994;	Paolo,	Troster,	&	Ryan,	1997)	and	
hence	the	CVLT-	II	manual	recommends	controlling	for	age	when	an-
alyzing	CVLT-	II	 performance	 (Delis	 et	al.,	 2000).	 In	 our	 sample,	 age	
was a statistically significant independent predictor of poorer verbal 
memory	performance	across	all	CVLT-	II	subscales,	which	may	be	due	
to a combination of normal cerebral aging processes leading to slower 
verbal memory processing—a finding consistent with prior reports 
in	mTBI	 (Jacobs	et	al.,	2010).	 It	should	be	noted	that	 in	our	sample,	
APOE-ε4(+) patients were on average 10 years older than ε4(−) pa-
tients, which may further compound their decreased verbal memory 
performance of the ε4-	carriers.	This	also	constitutes	a	limitation	of	the	
current analysis, and future studies should incorporate ε4(+) and ε4(−) 
cohorts matched by age (e.g., APOE-ε4(+) individuals vs. APOE-ε4(−) 
“controls”) in the study design. Education years was also an inde-
pendent predictor of verbal memory outcomes following mTBI in the 
current analysis. Previous reports regarding education effects on the 
CVLT-	II	are	more	unclear;	Paolo	et	al.	(1997)	report	that	education	af-
fects	only	14%	of	CVLT-	II	indices,	and	Wiens	et	al.	(1994)	did	not	find	
a	consistent	contribution	of	education	to	CVLT-	II.	However,	educa-
tion is a known predictor of protracted return to work following mTBI 
(Stulemeijer,	 van	 der	Werf,	 Borm,	&	Vos,	 2007),	 in	 part	 as	 a	 proxy	
for	 baseline	 reading	 and	 literacy	 capabilities	 (Dotson,	 Kitner-	Triolo,	
Evans,	&	Zonderman,	2009;		Albert	&	Teresi,	1999;	),	as	well	as	postin-
jury coping/resilience, socioeconomic status, and social support.
The	 relationship	 between	 race	 and	CVLT-	II	 has	 been	 previously	
described (Delis et al., 2000; Nathoo et al., 2003). In our study, race 
was associated with CVLT performance after injury. The reason for 
this is unclear, and may be related to a variety of factors. The ε4 allele 
is	more	 common	 in	 individuals	of	African-	American/African	descent	
compared	with	Caucasians	(Farrer	et	al.,1997;	Kern	et	al.,	2015),	and	
evidence suggests that ε4	allele	effects	are	weaker	in	the	former	(Kaup	
et al., 2015). Caucasian patients are more likely to have better access 
to healthcare and rehabilitation following TBI (Gasquoine, 2009; ). 
Further,	recent	reports	show	that	African-	American	and	Hispanic	pa-
tients are less likely to be placed in acute rehabilitation (Shafi et al., 
2007). Hence, racial differences in access to care, and the quality of 
care received, may additionally influence CVLT performance following 
mTBI. APOE-ε4 has also been implicated in differential predilections 
for developing cerebrovascular disease across ethnicities (Gavett, 
John,	Gurnani,	Bussell,	&	Saurman,	2015).	These	represent	important	
future directions for the study of APOE in mTBI.
4.4 | Limitations
This study has a relatively small population (n = 114), which may have 
impacted the true strength of association between APOE-ε4(+) and 
short-	delay	recall	trials,	as	well	as	limiting	the	applicability	of	our	study	
to	all	mTBI	patients.	Due	to	our	small	sample	size,	we	were	unable	to	
control for additional confounders without risk of overfitting the re-
gression	model,	which	further	limits	the	generalizability	of	our	results.	
The deleterious impacts on verbal memory attributable to APOE were 
also	 relatively	 small,	 especially	 in	 context	 of	 positive	 CT	 pathology.	
While there is some evidence that APOE-ε2 may confer a protective ef-
fect	on	cognitive	health	(Suri,	Heise,	Trachtenberg,	&	Mackaey,	2013),	
we were not able to investigate this aside from APOE-ε4 effects due to 
small	sample	size.	While	we	controlled	for	race	using	multivariable	anal-
ysis, we were unable to assess differences attributable to APOE-ε4(+) 
within individual races. APOE	effects	 in	the	context	of	disparate	pat-
terns of cognitive decline by race (Gu et al., 2015) present an additional 
confounder	that	cannot	be	addressed	in	detail	by	this	study.	Also,	as	
the	CVLT-	II	was	administered	in	English,	patients	whose	first	language	
is not English may perform with subtle differences. While out of scope 
of	 the	current	analysis,	 the	 long-	term	associations	between	APOE-ε4 
and outcomes after mTBI also warrant further investigation; another 
study in 396 severe TBI patients found no clear differences between 
ε4-	carriers	and	noncarriers	on	neuropsychological	test	performance	at	
a	follow-	up	interval	of	15–26	years	postinjury	(Millar,	Nicoll,	Thornhill,	
Murray,	 &	 Teasdale,	 2003),	 while	 a	 separate	 study	 reports	 poorer	
cognitive functioning in APOE-ε4(+) individuals three decades after 
TBI	 (Isoniemi,	 Tenovuo,	 Portin,	Himanen,	&	Kairisto,	 2006;	 ).	 Finally,	
as stated previously, the attributable R2 change to APOE-ε4 status is 
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relatively	small	 in	 the	context	of	other	validated	predictors	 for	mTBI	
outcome, and the value of APOE as a target for therapeutic evaluation 
following mTBI remains to be determined pending future work toward 
elucidating molecular mechanisms, and defining the criteria for height-
ened surveillance and/or intervention.
The	TRACK-	TBI	 Pilot	 study	was	 also	 limited	 by	 the	variables	 of	
the NIH NINDS TBI CDEs version 1, which did not include the high-
est	 level	 of	 granularity	 for	 certain	 periinjury	measures,	 for	 example,	
scalar	duration	 in	minutes	and/or	hours	of	LOC	and	PTA	which	may	
have	been	useful	 for	 estimating	 relative	mTBI	 severity.	Additionally,	
the	NIH	NINDS	TBI	CDEs	version	1	 recommended	 follow-	up	using	
neurocognitive measures at the single time point of 6 months, which 
prevents analysis of verbal memory recovery over time. These is-
sues	will	be	better	addressed	by	the	 larger	sample	size	and	multiple	
postinjury outcomes assessment time points as part of the ongoing 
12-	center	Transforming	Research	and	Clinical	Knowledge	in	Traumatic	
Brain	 Injury	 study	 in	 the	 U.S.	 (TRACK-	TBI;	 http://tracktbi.ucsf.edu)	
and	 22-	country	 Collaborative	 European	 NeuroTrauma	 Effectiveness	
Research	in	Traumatic	Brain	Injury	(CENTER-	TBI;	http://www.center-tbi.
eu) study in the European Union (Maas et al., 2015).
5  | CONCLUSIONS
Presence of the APOE-ε4	allele	is	associated	with	decreased	long-	term	
verbal	memory	on	two	subscales	of	the	CVLT-	II	 independent	of	de-
mographics, injury history, and intracranial CT pathology, suggesting 
disruption to consolidation and retrieval processes following mTBI. 
These	results	support	and	extend	previous	findings	between	APOE-ε4 
and impaired cognitive function, and preliminarily strengthen the link 
between	long-	term	verbal	memory	deficits	after	mTBI	and	the	patho-
physiology of neurodegenerative disorders. Future prospective stud-
ies targeting APOE-ε4 are needed to validate these findings.
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